Endometrial cancer: molecular and therapeutic aspects
Autor: | Sofia Bouchlariotou, Panagiotis Tsikouras, Georg Friedrich von Tempelhoff, Alexandros Dafopoulos, Nikolaos Vrachnis, Georgios Galazios, Roland Csorba |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2013 |
Předmět: |
Oncology
medicine.medical_specialty Class I Phosphatidylinositol 3-Kinases Receptor ErbB-2 medicine.medical_treatment Disease Klinikai orvostudományok Pathogenesis Endometrium Phosphatidylinositol 3-Kinases Internal medicine medicine Adjuvant therapy PTEN Combined Modality Therapy Humans PI3K/AKT/mTOR pathway Postoperative Care biology business.industry Endometrial cancer PTEN Phosphohydrolase Obstetrics and Gynecology Orvostudományok medicine.disease Endometrial Neoplasms Radiation therapy Fertility Reproductive Medicine Chemotherapy Adjuvant Immunology biology.protein Female business |
Popis: | Endometrial cancer (EC) is the most commonly diagnosed gynecologic malignancy. Although early-stage EC is effectively treated surgically, commonly without adjuvant therapy, the treatment of high-risk and advanced disease is more complex. Chemotherapy has evolved into an important modality in high-risk early-stage and advanced-stage disease, and in recurrent EC. Multi-institutional trials are in progress to better define optimal adjuvant treatment for subsets of patients, as well as the role of surgical staging in reducing both overuse and underuse of radiation therapy. Understanding and identifying the molecular biology and genetics of EC are central to the development of novel therapies. A number of molecular and genetic events have been observed in ECs, which have enabled us to have a better understanding of the biology and development of the disease. For example, the PTEN/AKT pathway and its downstream targets and the mTOR pathway have been shown to play an important role in EC pathogenesis. This review summarizes the background of the known molecular alterations, and the management of patients with EC. |
Databáze: | OpenAIRE |
Externí odkaz: |